Clinical trial
Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck…
NCT00401401 · Genmab, Industry · Terminated
Key facts
| NCT number | NCT00401401 |
|---|---|
| Title | Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer |
| Official title | An Open-labeled Trial With a Dose-escalation Part and a Parallel Group Design(1) Investigating Zalutumumab, an Anti-EGF Receptor Antibody, in Combination With Chemo-Radiation as First Line Treatment of Patients With Cancer of the Head and Neck (1) The Parallel Group Part Was Cancelled |
| Lead sponsor | Genmab, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer, Squamous Cell Cancer |
| Intervention type | Drug, Procedure |
| Interventions | zalutumumab, cisplatin, Radiotherapy |
| Enrollment | 30 |
| Start date | Dec 1, 2006 |
| Primary completion | Oct 1, 2010 |
| Completion | Oct 1, 2010 |
| First posted | Nov 20, 2006 |
| Last update posted | Dec 23, 2011 |
| Countries | Belgium, France, Netherlands, Sweden, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: